ConductScience.org, home

Paper6973389

Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil.

Evans RM and 2 others. Cancer Res, 1981. Cited by 342 papers, by iCite.

Cite this record

ConductScience Library. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Papers, record 6973389. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6973389

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil.
PubMed
Journal
Cancer Res
PubMed
Year
1981
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
342
iCite
Relative citation ratio, by iCite
12.7
iCite
Revised in PubMed
2015-11-19
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Evans RMR M
2Laskin JDJ D
3Hakala MTM T

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
FluorouracilMajor topic
InosineMajor topic
LeucovorinMajor topic
Animals
Carcinoma
Cell Line
Deoxyribonucleosides
Deoxyribose
Deoxyuridine
Drug Synergism
Humans
Mice
Sarcoma, Experimental
Thymidine
Thymidylate Synthase

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA-04175NCI NIH HHSUnited StatesR01CA004175PubMed and NIHNIH RePORTER
CA-13038NCI NIH HHSUnited StatesP01CA013038PubMed and NIHNIH RePORTER

Download CSV of grants

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 342 citations.

PMIDTitleJournalYearIn PapersSource
42373224Analysis of Formimidoyltransferase Cyclodeaminase as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer.Cancer Genomics Proteomics2026https://conductscience.org/library/papers/42373224PubMed
37206081Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review.World J Gastrointest Surg2023https://conductscience.org/library/papers/37206081PubMed
36183444A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.ESMO Open2022https://conductscience.org/library/papers/36183444PubMed
26189513
Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.
Invest New Drugs2015https://conductscience.org/library/papers/26189513PubMed
24276379Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Pharmaceuticals (Basel)2013https://conductscience.org/library/papers/24276379PubMed
16568373Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines.J Gastroenterol2006https://conductscience.org/library/papers/16568373PubMed
16222443Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study.Pharm Res2005https://conductscience.org/library/papers/16222443PubMed
15292717A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.Invest New Drugs2004https://conductscience.org/library/papers/15292717PubMed
15122082A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.Invest New Drugs2004https://conductscience.org/library/papers/15122082PubMed
14562021
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Br J Cancer2003https://conductscience.org/library/papers/14562021PubMed
12775023Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.Gastric Cancer2003https://conductscience.org/library/papers/12775023PubMed
12003195Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).Invest New Drugs2002https://conductscience.org/library/papers/12003195PubMed
9834413Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole.J Gastrointest Surg1998https://conductscience.org/library/papers/9834413PubMed
9045902Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3'-azido-3'-deoxythymidine for the gastric cancer cell line MKN28 in vivo.Jpn J Cancer Res1997https://conductscience.org/library/papers/9045902PubMed
8852401How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.Med Oncol1995https://conductscience.org/library/papers/8852401PubMed
8690753Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats.J Cancer Res Clin Oncol1996https://conductscience.org/library/papers/8690753PubMed
8369613The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.Surg Today1993https://conductscience.org/library/papers/8369613PubMed
8198932Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.Br J Clin Pharmacol1994https://conductscience.org/library/papers/8198932PubMed
8174202Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8174202PubMed
8126062Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.J Cancer Res Clin Oncol1994https://conductscience.org/library/papers/8126062PubMed

See all 54 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TYMS7298PubTator's text mininghttps://conductscience.org/library/genes/7298

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6973389

GET https://conductscience.org/api/papers/v1/6973389/cited_by?page=2